Icatibant in Severe Acute Respiratory Syndrome Coronavirus 2: a case description

Pecori D¹, Della Siega P², Sozio E³, Barbano E³, Mazzoran L³, Zanichelli A⁴, Sbrana F⁵, Federico I³, Bassi F⁶, Fabris M⁷, Vendramin I⁸, Sbrojavacca R¹, Tascini C¹

¹SOC Malattie Infettive, Azienda Sanitaria Universitaria Integrata di Udine, Udine - Italy
²North-West District, Tuscany Health Care, Spedali Riuniti Livorno, Emergency Department, Livorno – Italy
³Medicina D’Urgenza e Pronto Soccorso, Azienda Sanitaria Universitaria Integrata di Udine, Udine - Italy
⁴U.O. Medicina Generale, ASST Fatebenefratelli Sacco, Ospedale “Luigi Sacco”, Milano - Italy
⁵U.O. Lipoapheresis and Center for Inherited Dyslipidemias - Fondazione Toscana Gabriele Monasterio, Via Moruzzi, 1 - Pisa, Italy
⁶SOC Anestesia e Rianimazione 2, Azienda Sanitaria Universitaria Integrata di Udine, Udine - Italy
⁷Institute of Clinical Pathology, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy.
⁸Cardiothoracic Department; Division of Cardiac Surgery, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy.

Corresponding Author (1):
Carlo Tascini, MD
U.O. Malattie Infettive
Azienda Sanitaria Universitaria Integrata di Udine
Via Pozzuolo, 330
33100 Udine, ITALY
Phone: +39 0432 559355
Fax: +39 0432 559371
E-mail: c.tascini@gmail.com

Corresponding Author (2):
Francesco Sbrana, MD
U.O. Lipoaferesi
Fondazione Toscana “Gabriele Monasterio”
Via Moruzzi, 1
56124 Pisa, ITALY
Phone: +39 050 3153396
Fax: +39 050 3153030
E-mail: francesco.sbrana@ftgm.it

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.18176/jiaci.0659
In late 2019, the coronavirus SARS-CoV-2 was identified in Wuhan, China [1]. The WHO named COVID-19 the disease induced by the virus. There is evidence that excessive activity of bradykinin (BK) at pulmonary level correlates to severe interstitial and Severe Acute Respiratory Syndrome (SARS) pathogenesis. BK binding to Bradykinin 2 Receptors (BK2R) increases vascular permeability leading to pulmonary edema and release of proinflammatory mediators. SARS-CoV-2 uses Angiotensin-Converting enzyme 2 (ACE2) as the most suitable receptor to infect human cells [2]. Lack of ACE2 function results in the accumulation of Angiotensin II (ANG II) and this may cause a secondary reduction in the activity of Angiotensin-Converting Enzyme (ACE), with consequent increase of BK. Indeed, ACE catabolizes not only ANG I to ANG II conversion but it is also able to inactivate BK [3].

ACE2 is needed to inactivate des-Arg9 bradykinin (DABK), a bioactive metabolite of BK [4] that binds the bradykinin receptor type 1 (BK1R). In contrast to BK2R, the BK1R on endothelial cells is upregulated by proinflammatory cytokines. Lack of ACE2 leads to the inactivation of BK1R ligands, thus increasing DABK levels.

Furthermore, DABK weakly binds BK2R in certain tissues, and exerts effects that are blocked by the BK2R blocker Icatibant [4]. Icatibant is a selective antagonist of the BK2R, approved for treatment of acute attacks of hereditary angioedema [5]. Icatibant may interrupt the positive feedback loop of DABK- and BK-mediated inflammation and injury, improving clinical outcomes in patients with COVID-19 respiratory complications [4]. The use of off-label Icatibant (FIRAZYR®, manufactured by Shire, Zug - Switzerland, and now part of Takeda), blocking the increase in vascular permeability mediated by BK, may inhibit pulmonary edema in COVID-19.
We describe the case of a 56-year-old man, admitted for COVID-19 pneumonia in absence of comorbidity. Ten days after the onset of symptoms dyspnea occurred. At the hospital admission, the patient had the following arterial blood gas analysis: pH 7.5, PaO₂ 53 mmHg, pCO₂ 32 mmHg, with PaO₂/FiO₂ 252 and the alveolar–arterial gradient of 57.

The chest-CT revealed extensive peripheral dense ground-glass opacities with > 50% involvement. The patient received treatment with darunavir/cobicistat, hydroxychloroquine and antibiotic therapy (see Supplementary Figure).

The patient’s respiratory condition rapidly worsened in the first 24 hours upon arriving at the hospital: PaO₂/FiO₂ decreased to 205 despite high-flow oxygen therapy. Patient needed to be treated with non-invasive ventilation (helmet CPAP – PEEP 5 cmH₂O – FiO₂ 0.40 mmHg).

Because of the respiratory symptoms worsening despite these treatments, Icatibant was started on the second day of hospitalization: the patient received off-label Icatibant 30 mg subcutaneously every 8 hours for 3 days.

After administration of Icatibant, the patient presented a progressive clinical improvement and a reduction in: C reactive protein (from 67 to 10 mg/L), Interleukin 6 (IL-6, from 111 to 6 pg/ml), Interleukin 8 (IL-8, from 70 to 24 pg/ml), TNF-α (from 20 to 13 pg/ml) and IFN-γ (from 9.9 to 5.6 pg/ml).

Weaning by non-invasive ventilation occurred on the fourth day upon hospital admission when the patient had the following arterial blood gas analysis in Venturi Mask, with FiO₂ 0.40 mmHg: pH 7.53, PaO₂ 109 mmHg, pCO₂ 33 mmHg, with PaO₂/FiO₂ 290. Patient was discharged on day 12 without need of supplemental oxygen.

Icatibant is effective in angioedema caused by ACE-inhibitors and in treating breathing difficulty in patients presenting with angioedema; we have to keep in mind that COVID-19 causes dry cough, a typical side effect of ACE-inhibitors, linked to increase bradykinin level [6].

In our clinical case, there was a significant reduction of inflammatory cytokines and C reactive protein, suggesting a potential anti-inflammatory effect of Icatibant as a complementary treatment in COVID-19 SARS. Furthermore, Icatibant therapy was able to reduce IL-8 level, in fact this cytokine may be stimulate by BK in airway. Also, this finding supports the empirical use of Icatibant in the treatment of unremitting
respiratory distress in COVID-19 [7].

This case-report has some limitations, such as incapability to generalize and no possibility to establish cause-effect relationship between the use of Icatibant and the observed clinical improvement in patient.

Another limitation is the absence of support for the safety of Icatibant at the dose used (30 mg every 8 hours for 3 days). The Icatibant summary of product characteristics show that ≤8 Icatibant injections per month have been administered in clinical trials. The Icatibant package information recommends an interval of ≥6 h between doses and no more than three doses in 24 h [8]. However, in the Icatibant Outcome Survey registry, among 10 patients who received ≥9 Icatibant injections in 1 month, no adverse effects were reported in four patients who received Icatibant more frequently than three times in 24h [8]. As far as we know, the dose of 30 mg thrice a day for three consecutive days has been never used before in clinical practice. Due to the short half-life (1.48±0.35 hours), repeated subcutaneous administrations of Icatibant 30 mg at 6-hour intervals in healthy volunteers did not result into appreciable drug accumulation [9].

In the recent experience of van de Veerdonk et al., 10 patients were treated with 3 doses of 30 mg of Icatibant by subcutaneous injection at 6-hour intervals. Icatibant treatment was well tolerated in all 10 patients and in 8 patients a reduction of oxygen implementation was observed [10].

In our case report, the patient had an improvement of gas exchanges documented by arterial blood gas analysis and this allowed early weaning by non-invasive ventilation.

However, our patient was admitted to the hospital 10 days after the onset of symptoms. The second stage of COVID-19 is often characterized by pulmonary inflammation and coagulopathy. In this stage BK could play a relevant role in COVID-19: BK binds to B2-receptors, mediating vascular permeability, vasodilation and edema.

In conclusion, the off-label use of Icatibant, a B2R blocker, seems to be promising in the treatment of patients with respiratory distress caused by SARS-COV2.
Disclosures: C.T. has received funds for speaking at symposia organized on behalf of Pfizer, Novartis, Merck, Angelini, Zambon, Thermofischer, Biotest, Gilead, Hikma, Biomerieux and Astellas. A.Z. received speaker/consultancy fees and/or was a member of advisory boards for CSL Behring, Shire/Takeda, and SOBI. All other authors: None.

Acknowledgments: The authors thank Dr.Laura Sabatino for helpful English editing.

Funding: No financial support was received.
References


